查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1476336

到 2030 年异位性皮肤炎治疗药物的市场预测：按药物类别、严重程度、剂型、给药途径、用途和地区进行全球分析

Atopic Dermatitis Drugs Market Forecasts to 2030 - Global Analysis By Drug Class, Severity, Formulation, Route of Administration, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球异位性皮肤炎药物市场规模为 136.2 亿美元，预计 2030 年将达到 254.8 亿美元，预测期内复合年增长率为 8.1%。

异位性皮肤炎药物是指用于治疗异位性皮肤炎症状的药物，异位性皮肤炎是一种以搔痒、发红和皮疹为特征的慢性发炎皮肤病。透过解决潜在的免疫系统功能障碍，异位性皮肤炎治疗可以减缓疾病进展并最大限度地减少长期併发症。异位性皮肤炎治疗可以减缓疾病进展并增强皮肤的屏障功能，使患者能够更好地管理自己的病情并改善整体健康和生产力。

根据世界卫生组织（WHO）统计，2017年有超过9亿人患有皮肤病，其中五种常见皮肤病约占皮肤病的80%。异位性皮肤炎是一种常见的慢性发炎皮肤病，影响全球 15% 至 20% 的儿童和 1% 至 3% 的成人。

异位性皮肤炎增加

随着越来越多的患者寻求治疗，对有效药物治疗的需求也增加。需求的激增刺激了研究和开发工作，并导致了创新治疗方法的推出。此外，不断扩大的患者群体为製药公司创造了更大的市场机会，鼓励对药物开发和行销策略的投资。因此，异位性皮肤炎盛行率的上升直接推动了异位性皮肤炎治疗药物市场的成长。

副作用和安全问题

异位性皮肤炎药物的副作用和安全性问题包括免疫抑制、感染疾病风险增加、皮肤刺激和过敏反应。这些副作用限制了某些药物的使用并影响患者的用药顺从性和治疗结果。此外，安全问题会增加监管审查、延长核准流程并增加开发成本。频繁的副作用也会导致患者不满意，降低对现有治疗方法的信心，并阻碍市场成长。

医疗保健支出增加

医疗保健支出的增加增加了患者获得治疗选择的机会。分配给医疗保健的更多财政资源将使人们能够负担昂贵的生物製药和异位性皮肤炎的新疗法。此外，医疗保健支出的增加通常与基础设施、医疗保健服务和病患教育的改善有关，从而导致更早诊断和开始治疗。总体而言，医疗保健支出的成长趋势正在创造有利于异位性皮肤炎治疗药物的市场扩张和创新的环境。

非专利衝突

当原厂药的专利到期并且学名药製造商能够以更低的价格生产和销售同等产品时，就会出现特应性皮肤炎治疗学名药的竞争。结果，製药公司的盈利较低，投资于创新治疗方法研发的奖励也较少。此外，学名药竞争限制了患者获得新的和可能更有效的治疗方法，影响了整体市场需求和成长。

COVID-19 的影响

COVID-19 的爆发对异位性皮肤炎治疗药物市场产生了重大影响。医疗服务的关闭和中断导致异位性皮肤炎患者的诊断和治疗开始延迟。此外，经济不确定性减轻了患者的经济负担，并减少了获得昂贵生物製药的机会。新疗法的临床试验也面临延误，影响了管线进展。整体而言，市场挑战与机会并存，对成长和创新有长期影响。

锭剂市场预计将在预测期内成为最大的市场

锭剂市场预计将出现良好的成长。异位性皮肤炎是一种慢性发炎皮肤病，通常透过口服锭剂药物进行治疗。这些药物旨在缓解搔痒、发炎和皮疹等症状。当异位性皮肤炎广泛或严重时，它尤其有效。这些锭剂是治疗异位性皮肤炎的综合方法的一部分，通常与局部治疗和生活方式改变相结合。

预计发炎领域在预测期内复合年增长率最高

预计发炎领域在预测期内将出现最高的复合年增长率。异位性皮肤炎是一种慢性发炎皮肤病，有多种针对发炎的药物干预措施。调节免疫反应和减少发炎可以预防疾病发作并促进长期缓解。整体而言，发炎作用不仅可以缓解不适，还可以降低与慢性异位性皮肤炎相关的併发症的风险。

比最大的地区

由于盛行率上升、医疗保健支出增加以及对异位性皮肤炎的认识不断增强，预计亚太地区将在预测期内占据最大的市场占有率。日本、中国和韩国等国家由于患者人数众多且医疗保健机会的改善，为市场扩张做出了重大贡献。此外，製药公司和当地医疗保健提供者之间的合作正在推动市场渗透。总体而言，在不断发展的医疗基础设施和不断提高的患者意识的推动下，亚太地区的异位性皮肤炎治疗市场预计将持续扩张。

复合年增长率最高的地区：

由于异位性皮肤炎的高发病率、先进的医疗基础设施以及研发方面的高投资，预计北美在预测期内将呈现最高的复合年增长率。美国主导市场，大部分收益来自生物製药和局部皮质类固醇。此外，该地区完善的製药业和强大的法律规范支持创新治疗方法的开发和商业化。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球异位性皮肤炎治疗药物市场：依药物类别

  • 皮质类固醇
  • Calcineurin抑制剂
  • 全身性免疫抑制剂
  • 磷酸二酯酶 4 (PDE4) 抑制剂
  • 抗组织胺药
  • 其他药物类别

第六章全球异位性皮肤炎治疗药物市场：依严重程度分类

  • 轻微症状
  • 中度疾病
  • 病情严重

第七章全球异位性皮肤炎治疗药物市场：按剂型

  • 锭剂
  • 洗剂
  • 糖浆
  • 喷
  • 其他剂型

第八章全球异位性皮肤炎治疗药物市场：途径

  • 外用药
  • 口腔医学
  • 注射药物

第九章全球异位性皮肤炎治疗药物市场：依应用分类

  • 照光治疗
  • 免疫调节
  • 预防感染
  • 皮肤屏障功能障碍
  • 发炎
  • 痒
  • 其他用途

第十章全球异位性皮肤炎治疗药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Sanofi
  • Regeneron Pharmaceuticals
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • LEO Pharma A/S
  • Galderma SA
  • Johnson & Johnson
  • Bristol Myers Squibb
  • AnaptysBio Inc.
  • Encore Dermatology Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Glenmark Pharmaceuticals
Product Code: SMRC25882

According to Stratistics MRC, the Global Atopic Dermatitis Drugs Market is accounted for $13.62 billion in 2023 and is expected to reach $25.48 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Atopic Dermatitis Drugs refer to pharmaceuticals used to manage the symptoms of atopic dermatitis, a chronic inflammatory skin condition characterized by itching, redness, and rash. By addressing the underlying immune system dysfunction, these drugs help in controlling the disease progression and minimizing long-term complications. By controlling the disease progression and enhancing skin barrier function, atopic dermatitis drugs empower patients to better manage their condition, leading to improved overall well-being and productivity.

According to the World Health Organization (WHO), over 900 million people were affected with skin disease in 2017, and around 80% of the skin disorders are accounted for by the five common skin disorders. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% of children and 1% to 3% of adults across the world.

Market Dynamics:

Driver:

Rising incidence of atopic dermatitis

With an increasing number of patients seeking treatment, there is a growing demand for effective pharmaceutical interventions. This surge in demand stimulates research and development efforts, leading to the introduction of innovative therapies. Moreover, the expanding patient pool creates a larger market opportunity for pharmaceutical companies, encouraging investment in drug development and marketing strategies. Consequently, the rising prevalence of atopic dermatitis directly fuels the growth of the atopic dermatitis drugs market.

Restraint:

Side effects and safety concerns

Side effects and safety concerns in atopic dermatitis drugs include immunosuppression, increased risk of infections, skin irritation, and allergic reactions. These adverse effects limit the widespread use of certain medications, impacting patient adherence and treatment outcomes. Moreover, safety issues raise regulatory scrutiny, prolonging approval processes and increasing development costs. High incidences of side effects also lead to patient dissatisfaction, reducing confidence in available treatments and hindering market growth.

Opportunity:

Rising healthcare expenditure

Rising healthcare expenditure enhances patient access to treatment options. With greater financial resources allocated to healthcare, individuals can afford expensive biologic drugs and novel therapies for atopic dermatitis. Moreover, increased healthcare spending often correlates with improved infrastructure, healthcare services, and patient education, leading to earlier diagnosis and treatment initiation. Overall, the uptrend in healthcare expenditure creates a conducive environment for market expansion and innovation in atopic dermatitis therapeutics.

Threat:

Generic competition

Generic competition in atopic dermatitis drugs arises when patents for branded medications expire, allowing generic drug manufacturers to produce and sell equivalent versions at lower prices. As a result, pharmaceutical companies face decreased profitability and reduced incentives for investing in research and development of innovative treatments. Additionally, generic competition limits patient access to newer, potentially more effective therapies, impacting overall market demand and growth.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the atopic dermatitis drugs market. Lockdowns and disruptions in healthcare services have led to delays in diagnosis and treatment initiation for atopic dermatitis patients. Additionally, economic uncertainties have reduced patient affordability and access to expensive biologic drugs. Clinical trials for new treatments have also faced delays, affecting pipeline progress. Overall, the market has experienced a mix of challenges and opportunities, with long-term implications for growth and innovation.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Atopic dermatitis, a chronic inflammatory skin condition, is often managed through oral medications in tablet form. These drugs aim to alleviate symptoms such as itching, inflammation, and rash associated with the condition. They offer systemic relief, targeting inflammation from within, which can be particularly effective for widespread or severe cases of atopic dermatitis. These tablets are part of a comprehensive approach to managing atopic dermatitis, often combined with topical treatments and lifestyle modifications.

The inflammation segment is expected to have the highest CAGR during the forecast period

The inflammation segment is anticipated to witness the highest CAGR growth during the forecast period. Atopic dermatitis, a chronic inflammatory skin condition, sees several drug interventions targeting inflammation. By modulating immune responses and reducing inflammation, they can prevent disease flare-ups and promote long-term remission. Overall, their efficacy in controlling inflammation not only relieves discomfort but also mitigates the risk of complications associated with chronic atopic dermatitis.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to rising prevalence, increasing healthcare expenditure, and expanding awareness about the condition. Countries like Japan, China, and South Korea are key contributors to market expansion due to their large patient populations and improving access to healthcare. Additionally, partnerships between pharmaceutical companies and local healthcare providers facilitate market penetration. Overall, the Asia-Pacific Atopic Dermatitis Drugs Market is poised for continued expansion fuelled by evolving healthcare infrastructure and growing patient awareness.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to high prevalence of atopic dermatitis, sophisticated healthcare infrastructure, and significant investments in research and development. The United States dominates the market, with a significant portion of revenue attributed to biologic drugs and topical corticosteroids. Further, the region's well-established pharmaceutical industry and strong regulatory framework support the development and commercialization of innovative therapies.

Key players in the market

Some of the key players profiled in the Atopic Dermatitis Drugs Market include Sanofi, Regeneron Pharmaceuticals, Pfizer Inc., Novartis AG, Eli Lilly and Company, AbbVie Inc., Astellas Pharma Inc., LEO Pharma A/S, Galderma S.A., Johnson & Johnson, Bristol Myers Squibb, AnaptysBio Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, AstraZeneca PLC and Glenmark Pharmaceuticals.

Key Developments:

In January 2024, Pfizer and Glenmark Pharmaceuticals announced that they had collaborated to launch abrocitinib, an oral treatment for moderate-to-severe atopic dermatitis (AD) in India. Pfizer developed abrocitinib, which has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO). Glenmark and Pfizer will co-market the product under the brand names Jabryus and Cibinqo, respectively.

In January 2024, Sanofi's Dupixent (dupilumab) has been approved for use in treating moderate to severe atopic dermatitis in patients aged 12 and older in the European Union. It is also the first and only biologic medicine in India that has shown improved disease signs, symptoms, and quality of life measures for atopic dermatitis.

Drug Classes Covered:

  • Corticosteroids
  • Calcineurin Inhibitors
  • Systemic Immunosuppressants
  • Phosphodiesterase-4 (PDE4) Inhibitors
  • Antihistamines
  • Other Drug Classes

Severities Covered:

  • Mild
  • Moderate
  • Severe

Formulations Covered:

  • Tablets
  • Lotions
  • Syrups
  • Sprays
  • Other Formulations

Route of Administrations Covered:

  • Topical Drugs
  • Oral Drugs
  • Injectable Drugs

Applications Covered:

  • Phototherapy
  • Immunomodulation
  • Infection Prevention
  • Skin Barrier Dysfunction
  • Inflammation
  • Itching
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atopic Dermatitis Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Corticosteroids
  • 5.3 Calcineurin Inhibitors
  • 5.4 Systemic Immunosuppressants
  • 5.5 Phosphodiesterase-4 (PDE4) Inhibitors
  • 5.6 Antihistamines
  • 5.7 Other Drug Classes

6 Global Atopic Dermatitis Drugs Market, By Severity

  • 6.1 Introduction
  • 6.2 Mild
  • 6.3 Moderate
  • 6.4 Severe

7 Global Atopic Dermatitis Drugs Market, By Formulation

  • 7.1 Introduction
  • 7.2 Tablets
  • 7.3 Lotions
  • 7.4 Syrups
  • 7.5 Sprays
  • 7.6 Other Formulations

8 Global Atopic Dermatitis Drugs Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Topical Drugs
  • 8.3 Oral Drugs
  • 8.4 Injectable Drugs

9 Global Atopic Dermatitis Drugs Market, By Application

  • 9.1 Introduction
  • 9.2 Phototherapy
  • 9.3 Immunomodulation
  • 9.4 Infection Prevention
  • 9.5 Skin Barrier Dysfunction
  • 9.6 Inflammation
  • 9.7 Itching
  • 9.9 Other Applications

10 Global Atopic Dermatitis Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Sanofi
  • 12.2 Regeneron Pharmaceuticals
  • 12.3 Pfizer Inc.
  • 12.4 Novartis AG
  • 12.5 Eli Lilly and Company
  • 12.6 AbbVie Inc.
  • 12.7 Astellas Pharma Inc.
  • 12.8 LEO Pharma A/S
  • 12.9 Galderma S.A.
  • 12.10 Johnson & Johnson
  • 12.11 Bristol Myers Squibb
  • 12.12 AnaptysBio Inc.
  • 12.13 Encore Dermatology Inc.
  • 12.14 GlaxoSmithKline PLC
  • 12.15 AstraZeneca PLC
  • 12.16 Glenmark Pharmaceuticals

List of Tables

  • Table 1 Global Atopic Dermatitis Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Atopic Dermatitis Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Atopic Dermatitis Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 4 Global Atopic Dermatitis Drugs Market Outlook, By Calcineurin Inhibitors (2021-2030) ($MN)
  • Table 5 Global Atopic Dermatitis Drugs Market Outlook, By Systemic Immunosuppressants (2021-2030) ($MN)
  • Table 6 Global Atopic Dermatitis Drugs Market Outlook, By Phosphodiesterase-4 (PDE4) Inhibitors (2021-2030) ($MN)
  • Table 7 Global Atopic Dermatitis Drugs Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 8 Global Atopic Dermatitis Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 9 Global Atopic Dermatitis Drugs Market Outlook, By Severity (2021-2030) ($MN)
  • Table 10 Global Atopic Dermatitis Drugs Market Outlook, By Mild (2021-2030) ($MN)
  • Table 11 Global Atopic Dermatitis Drugs Market Outlook, By Moderate (2021-2030) ($MN)
  • Table 12 Global Atopic Dermatitis Drugs Market Outlook, By Severe (2021-2030) ($MN)
  • Table 13 Global Atopic Dermatitis Drugs Market Outlook, By Formulation (2021-2030) ($MN)
  • Table 14 Global Atopic Dermatitis Drugs Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 15 Global Atopic Dermatitis Drugs Market Outlook, By Lotions (2021-2030) ($MN)
  • Table 16 Global Atopic Dermatitis Drugs Market Outlook, By Syrups (2021-2030) ($MN)
  • Table 17 Global Atopic Dermatitis Drugs Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 18 Global Atopic Dermatitis Drugs Market Outlook, By Other Formulations (2021-2030) ($MN)
  • Table 19 Global Atopic Dermatitis Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 20 Global Atopic Dermatitis Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
  • Table 21 Global Atopic Dermatitis Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
  • Table 22 Global Atopic Dermatitis Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
  • Table 23 Global Atopic Dermatitis Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Atopic Dermatitis Drugs Market Outlook, By Phototherapy (2021-2030) ($MN)
  • Table 25 Global Atopic Dermatitis Drugs Market Outlook, By Immunomodulation (2021-2030) ($MN)
  • Table 26 Global Atopic Dermatitis Drugs Market Outlook, By Infection Prevention (2021-2030) ($MN)
  • Table 27 Global Atopic Dermatitis Drugs Market Outlook, By Skin Barrier Dysfunction (2021-2030) ($MN)
  • Table 28 Global Atopic Dermatitis Drugs Market Outlook, By Inflammation (2021-2030) ($MN)
  • Table 29 Global Atopic Dermatitis Drugs Market Outlook, By Itching (2021-2030) ($MN)
  • Table 30 Global Atopic Dermatitis Drugs Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.